[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500192":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":20,"armGroups":32,"interventions":44,"overallOfficials":58,"centralContacts":62,"locations":67,"responsibleParty":82,"collaborators":20,"id":84,"slug":20,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":20,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":20,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Damanhour Teaching Hospital","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":20},[9,13],{"measure":10,"description":11,"timeFrame":12},"Median and Range of Numeric Pain Rating Scale (NPRS) score [(median (range)]","NPRS measures the severity of pain, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain ( At post anesthesia care unit (PACU), then every 2 hours till 24 hours)","24 hours after the end of the operation",{"measure":14,"description":15,"timeFrame":12},"Mean and Standard deviation of Numeric Pain Rating Scale (NPRS) score (mean±SD)","NPRS measures the severity of pain, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain ( At PACU, then every 2 hours till 24 hours)",[17],{"measure":18,"description":19,"timeFrame":12},"Number of participants and Percentage of Drug-related side effects","Number of participants and Rate of: Bradycardia, Hypotension, Dysrhythmia, and Postoperative nausea and vomiting (PONV)",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":26,"maskingDescription":20,"whoMasked":27},"QUADRUPLE",[28,29,30,31],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[33,39],{"label":34,"type":35,"description":36,"interventionNames":37},"Group A (n=30)","ACTIVE_COMPARATOR","Dexmedetomidine group",[38],"Drug: Dexmedetomidine Hydrochloride",{"label":40,"type":35,"description":41,"interventionNames":42},"Group B (n=30)","Dexamethasone group",[43],"Drug: Dexamethasone Phosphate",[45,52],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"DRUG","Dexmedetomidine Hydrochloride","Dexmedetomidine 50 Mcg",[34],[51],"Precedex",{"type":46,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Dexamethasone Phosphate","Dexamethasone 4 mg",[40],[57],"Dexamethasone",[59],{"name":60,"affiliation":5,"role":61},"Ahmed M Shaat, MD","PRINCIPAL_INVESTIGATOR",[63],{"name":60,"role":64,"phone":65,"phoneExt":20,"email":66},"CONTACT","00201223482709","ahmedshaat99@gmail.com",[68],{"facility":5,"status":69,"city":70,"state":71,"zip":20,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"RECRUITING","Damanhūr","El-Beheira","Egypt","EG",{"type":75,"coordinates":76},"Point",[77,78],30.95,27.38333,{"lat":78,"lon":77},[81],{"name":60,"role":64,"phone":65,"phoneExt":20,"email":66},{"type":83,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100500192",false,"NCT05793060","Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block","Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Ultrasound-guided Intermediate Cervical Plexus Block in Patients Undergoing Thyroidectomy","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status ≤ II\n* Age from 21 to 60 years\n* Body Mass Index (BMI) ≤ 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* ASA physical status \\> II\n* Age \\\u003C 21 years or \\> 50 years\n* BMI \\> 35 kg\u002Fm2\n* Bronchial asthma\n* Chronic obstructive pulmonary disease\n* Restrictive lung diseases\n* Sick sinus syndrome\n* Sinus bradycardia\n* Hypertension\n* Chronic hypotension\n* Ischemic heart disease\n* Coagulopathies\n* Hepatic insufficiency\n* Renal insufficiency\n* Diabetes mellitus\n* Peripheral neuropathy\n* Thyroid malignancy\n* Hyperthyroidism\n* Substernal goiter\n* Patients on beta-blockers\n* Patients using pacemakers\n* Alcohol or drug abuse\n* Allergy to the study drugs","ALL","21 Years","60 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98],"PHASE4","Background: Many thyroidectomy patients suffer from postoperative pain that could delay early hospital discharge and place a significant burden on both the patient and the healthcare team. Bilateral intermediate cervical plexus block (ICPB) provides good analgesia for neck surgery, including thyroidectomy. However, the duration of a single-shot nerve block is usually short. Therefore, adjuvants are used in peripheral nerve blocks.\n\nObjectives: To compare the safety and efficacy of dexmedetomidine versus dexamethasone as adjuvants to bupivacaine in ultrasound-guided intermediate cervical plexus block in patients undergoing total thyroidectomy under general anesthesia.\n\nPatients and Methods: This is a randomized, double-blind, phase four, prospective clinical trial; carried out on 60 patients, who were candidates for total thyroidectomy under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received bilateral ICPB with isobaric bupivacaine plus dexmedetomidine, and group B, received bilateral ICPB with isobaric bupivacaine plus dexamethasone.",[101],"Analgesia",[103,57,104,105],"Cervical plexus block","Dexmedetomidine","Thyroidectomy","2026-01-09",{"date":108,"type":109},"2026-01-12","ACTUAL",{"date":111,"type":109},"2025-08-01",{"date":113,"type":95},"2026-12-15",{"name":5,"class":6},1]